Radiosurgery systems maker,
) announced that U.S.-based Lancaster General Health is the first
to use its latest CyberKnife M6 system for treating patients.
This unique system is capable of treating large, complicated
tumors (which were rendered untreatable earlier), thereby
increasing the number of patients who can benefit from this
ACCURAY INC (ARAY): Free Stock Analysis
MYRIAD GENETICS (MYGN): Free Stock Analysis
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.
The CyberKnife system is a non-invasive alternative to
traditional surgery and is the first and only commercially
available intelligent robotic radiosurgery system designed to
treat solid tumors anywhere in the body.
The CyberKnife M6 FIM and FM Systems feature the unique InCise
Multileaf Collimator ("MLC"), specially designed for stereotactic
radiosurgery (SRS) and stereotactic body radiation therapy (SBRT)
treatments. The flexibility of MLC helps deliver precise and
accurate radiation dosages from multiple angles in less time, and
thus improves the efficacy and treatment outcomes in the field of
Its special features include a 3D robot, which can revolve around
the patient in order to deliver non-isocentric, non-coplanar
radiations to match the exact shape of the tumor. The InCise
MLC's capability is further enhanced when combined with
CyberKnife's Synchrony System, which allows the CyberKnife M6
System to locate tumors while moving and instantly rectifying for
their movement during treatment.
The company had launched the unmatched CyberKnife M6 System at
the ASTRO meeting in 2012. The system was approved by the U.S.
Food and Drug Administration (FDA) in Nov 2012. In Feb 2013, the
European CyberKnife Center Munich-Grosshadern (ECZM), a global
pioneer in radiosurgery, treated the world's first patient with
the CyberKnife M6 System.
Although we are impressed with the progress in the adoption of
Accuray's CyberKnife M6, a lot needs to be done to bring the
company back on track. We remain concerned over Accuray's
declining top and bottom line along with reduced full-year
guidance. Management needs to improve its higher-margin product
revenues and aggressively remediate its structural issues for new
offerings to fully contribute to total sales.
Moreover, Accuray remains susceptible to the weak U.S. and
European markets, reimbursement uncertainties and faces stiff
challenges from competitive product offerings. The product line
faces stiff competition from
Varian Medical System
) TrueBeam technology.
Accuray has a Zacks Rank #4 (Sell). While we prefer to avoid the
stock, other medical stocks such as
) warrant a look. These stocks carry a Zacks Rank #1 (Strong